DELTA CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF Abstract Delta crystalline form of the compound of formula (I): : N CO~ I H 2 N NH H CHH3 H 3 (s) " NH 2 (s) CO2Et characterised by its X-ray powder diffraction diagram. Medicaments and methods of medical treatment are also disclosed.

The present invention relates to novel and stable polymorphic forms of Perindopril (L)-Arginine designated as Form and amorphous form and processes for their preparation. The present invention also provides the novel polymorph Form with greater stability to heat and humidity and can be prepared on large scale by an efficient, economic and reproducible process.

Process for industrial synthesis of (2S 3aS 7aS)-1-(S) alanyl octahydro-2-carboxylic acid derivatives (I) by reaction of alanine derivative (VI) and ester derivative (V) and catalytic hydrogenation. Process for industrial synthesis of (2S 3aS 7aS)-1-(S) alanyl octahydro-2-carboxylic acid derivatives of formula (I) comprises reaction of an ester of formula (V) with an alanine of formula (VI) in an organic solvent optionally in the presence of less than 0.6 mole per mole (V) of 1-hydroxybenzotri...

The present invention relates to A microcapsule composition allowing the delayed and controlled release of perindopril or of a pharmaceutically acceptable salt thereof for administration by the oral route.

Novel polymorphic forms of perindopril (L)-arginine and process for the preparation thereof The present invention relates to novel and stable polymorphic forms of Perindopril (L)- Arginine designated as Form Yand amorphous form and processes for their preparation. The present invention also provides the novel polymorph Form y with greater stability to heat and humidity and can be prepared on large scale by an efficient, economic and reproducible process.